Human Vaccines: Market Research Report

Date: March 1, 2012
Pages: 821
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H9F81E7134EEN
Leaflet:

Download PDF Leaflet

Human Vaccines: Market Research Report
This report analyzes the worldwide markets for Prophylatic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report also analyzes the world market for Therapeutic Vaccines for the period 2010 to 2015.

The report profiles 162 companies including many key and niche players such as ALK - Abelló A/S, Bavarian Nordic A/S, Crucell N.V., CSL Ltd., GlaxoSmithKline PLC, GlaxoSmithKline Biologicals S.A, Medimmune, Inc., Merck & Company, Inc., Novartis Vaccines & Diagnostics, Inc., Sanofi, Sanofi-Pasteur SA, Sanofi Pasteur, Inc., Shanta Biotechnics Ltd., Vaxin, Inc., and Wyeth.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Prophylactic Vaccines
Therapeutic Vaccines

II. EXECUTIVE SUMMARY1. MARKET OVERVIEW & OUTLOOK

Human Vaccines Market Remains Resilient to Recession
Global Human Vaccines Market: A Snapshot
Market Dynamics
Vaccine Pricing: The Developed – Developing Divide
Growth Drivers in a Capsule
Developed World: The Key Markets
Looking Ahead
Emerging Markets: The Future Growth Area
Competitive Scenario
World’s Leading Producers

Table 1. Leading Players in the Worldwide Vaccines Market (2008): Market Share Breakdown by Value Sales for GlaxoSmithKline, Sanofi-Aventis, Merck & Co. , Novartis, Wyeth, and Others (includes corresponding Graph/Chart)

ALK- The Global Leader in Allergy Vaccines

Table 2. Leading Players in the Worldwide Allergy Vaccines Market (2005 & 2006 - A Historic Perspective): Market Share Breakdown of Value Sales (*) for ALK- Abelló, Stallergenes, Allergopharma, and Others (includes corresponding Graph/Chart)

2. PRODUCT OVERVIEW

Introduction to the Concept of Immunity
Role of Vaccines in Strengthening the Immune System
Vaccines and Immunotherapy
Historical Overview of Vaccines
How it Began
So Far So Good
Successful Vaccine Introductions in the Past
Contribution of Animal Research to Vaccine Production
Types of Vaccines
Live, Attenuated Vaccines
Combination Vaccines
Killed or Inactivated Vaccines
DNA & Recombinant DNA Vaccines
Toxoids
Cellular Fractions
Conjugate Vaccines
Subunit Vaccines
Passive Immunization
Prophylactic Vaccines
Prevention Better than Cure
Prophylactic Pediatric Vaccines
Vaccination Over the Years
A Mature Market
Challenges for Pediatric Vaccines Market
BCG Vaccine
Growth Boosting Factors for TB Vaccines
Demand Restraining Factors for TB Vaccines
Major Issues to be Addressed in the TB Vaccine Market

Table 3. Global Historic Review for TB Vaccines Market: Annual Sales for Years 2000 through 2005 (In US$ Million) (includes corresponding Graph/Chart)

Hemophilus Influenza Type B Vaccine
Hib and Combination Vaccines by Producer

Table 4. Historic Review for Pediatric Haemophilis Influenza B Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
Table 5. Historic Review for Pediatric Haemophilis Influenza B Vaccine Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)

Diphtheria/Tetanus/Pertussis Vaccines
DTP, DTaP, and Combination Vaccines Offered by Major Producers in US

Table 6. Leading Players in the US DTP and DTaP Vaccines Market (2003-2005 – A Historic Review): Market Share Breakdown of Value Sales for Sanofi Pasteur, Wyeth, GlaxoSmithkline, and others (includes corresponding Graph/Chart)
Table 7. Historic Review of DTP and DTaP Vaccines Market in the US: Annual Sales for 2000- 2005 (In US$ Million) (includes corresponding Graph/Chart)
Table 8. Historic Review of DTP Vaccine Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)

Hepatitis A Vaccine
Hepatitis B Vaccine
Hepatitis B Epidemiology

Table 9. World Market for Hepatitis B Vaccines: Annual Sales for Years 2009 through 2017 (In US $ Million) (includes corresponding Graph/Chart)
Table 10. Historic Review for Hepatitis B Vaccines Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)

Measles/Mumps/Rubella Vaccines

Table 11. Historic Review for Measles-Mumps- Rubella (MMR) Vaccine Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
Table 12. Historic Review for Measles-Mumps-Rubella (MMR) Vaccine Market in the US: Annual Sales for 2000-2005 (In Millions of Doses) (includes corresponding Graph/Chart)

Rotavirus Vaccines
Polio Vaccines

Table 13. Historic Review for Polio Vaccines Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
Table 14. Historic Review for Polio Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
Table 15. Historic Review for Polio Vaccine Market for Both Vaccine Types in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)
Table 16. Historic Review for Polio Vaccine Market for Both Vaccine Types (OPV and IPV) in the US in Percent of Doses from 2000-2005

Varicella Vaccine

Table 17. Historic Review for Varicella Vaccine Market in the US and Europe: Annual Sales for 2000- 2005 (In US$ Million) (includes corresponding Graph/Chart)
Table 18. Historic Review for Varicella Vaccines Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)

Need for Combination Vaccines
Prophylactic Adult Vaccines
Favorable Market Growth
Hepatitis A Vaccine
Hepatitis B Vaccines
Key Issues Affecting the Adult Hepatitis Vaccines Market
Cholera Vaccine
Hepatitis A/Hepatitis B Vaccine
Japanese Encephalitis Vaccines
Influenza Vaccines

Table 19. Global Flu Vaccines Market by Region (2005): Percentage Share Breakdown of Value Sales for the US, EU, and Rest of the World (includes corresponding Graph/Chart)
Table 20. Global Flu Vaccines Market by Leading Players (2005): Market Share Breakdown by Volume Sales for Sanofi Pasteur, Chiron, GSK and Others (includes corresponding Graph/Chart)
Table 21. Rate of Influenza Vaccine Consumption Among Target Groups (includes corresponding Graph/Chart)
Table 22. Global Historic Review for Adult Influenza Vaccines: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)

Growth Boosting Factors for Influenza Vaccines Market
Key Issues Affecting Influenza Vaccines Market
Age-Driven Strategies Drive Target Market for Influenza Vaccines
Healthcare Professionals Increase Target Market for Influenza Vaccines
Lyme Disease Vaccine
Pneumococcal Disease Vaccines
Meningococcal Vaccines
Rabies Vaccines

Table 23. Global Historic Review for Rabies Vaccines: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)

Typhoid Vaccine
Yellow Fever Vaccine
Need for Additional Vaccines
Therapeutic Vaccines
DNA Holds the Key
Huge Potential for Protein Based Vaccines
Therapeutic Hepatitis Vaccines
Therapeutic Addiction Vaccines
Cancer Vaccines
Human Papillomavirus (HPV) Vaccine
Breakthroughs in Cancer Vaccine Market
Factors Affecting the Market for Cancer Vaccines
Vaccine for AIDS
What is AIDS?
Global Statistics

Table 24. Worldwide HIV/AIDS – 2007 (includes corresponding Graph/Chart)
Table 25. Worldwide HIV & AIDS Incidences (2007): A Regional Breakdown for Living and Newly Infected Cases (includes corresponding Graph/Chart)
Table 26. Worldwide HIV & AIDS Prevalence Rate in Adults Aged between 15 and 49 Years for the Year 2007 (includes corresponding Graph/Chart)

Asia-Pacific
Central Asia & Eastern Europe
Commonwealth of Independent States (CIS)
Latin America (Including the Caribbean Islands)
Sub Saharan Africa
North Africa & the Middle East
Developed Regions and High-Income Countries
United States

Table 27. New HIV Infection Cases among Men in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)
Table 28. New HIV Infection Cases in the US (2006): Percentage Breakdown by Racial/Ethnic Groups (includes corresponding Graph/Chart)
Table 29. New HIV Infection Cases among Women in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)

Development of Treatment Options
Categories of Vaccines for AIDS
HIV Vaccines Under Development
HIV Vaccines (Prophylactic/Therapeutic) Under Development: As of 2010
Malaria Vaccine
Therapeutic Vaccines Against Infectious Diseases: The Challenges
Melanoma: Prospects for Treatment
Melanoma Vaccines under Development: As of 2010
Autoimmune Diseases
How Do Autoimmune Diseases Occur
Types of Autoimmune Diseases
Need for Developing Autoimmune Therapeutic Vaccines
Travel Vaccines: Opportunities
SARS – A Review
Vaccinations Recommended for Travel to High-Risk Areas
Mechanisms for Vaccine Delivery
Edible Vaccines
Oral Vaccines
Tablet Based Vaccines
Mucosal Delivery
Transdermal Patch Delivery

3. MARKET TRENDS & ISSUES

Newer Vaccines in Pipeline to Cheer Up Pharma Companies
Select Vaccines Currently in Phase III Clinical Trials
Threat of Pandemic Rejuvenates Vaccine Market
Influenza Vaccines On a Growing Spree
H1N1 Vaccines Hit the Market in August 2009
H1N1 Influenza Vaccines and Manufacturers
Influenza Market Faces Several Challenges
Economic Factors Hamper Optimal Vaccine Development and Delivery
Increasing Need for Vaccine Promotion in the Developing Regions
Changing Vaccine Needs
DNA Vaccines: Engineering Growth
AIDS Vaccine: Long Road Ahead
HIV Vaccines Research Clipped by Lack of Funds
Funding Drops In HIV Vaccine Research Amid Recession
Noninjectable Vaccines: Gain Without Pain
Need for a Human Vaccine for Leishmaniasis
Conjugate Vaccines: A Technological Innovation
Need For a New TB Vaccine

Table 30. Worldwide Prevalence of TB Cases (in ‘000s) by Region for the Year (2007) (includes corresponding Graph/Chart)

Companies Involved in TB Vaccine Research: As of 2010
Religious Concerns Over Immunizing Young Girls Against Human Papillomavirus
Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
DTaP Vaccines Approved for Booster Vaccination
Advances in Biotechnology Spearheading Vaccines’ Growth
BioWarfare: Threat Perception and Preparedness
Overview of Potential Bio-Terrorist Agents
Smallpox (Variola Major)
Anthrax (Bacillus Anthracis)
Plague (Yersinia Pestis)
Botulism (Clostridium Botulinum)
Tularemia (Francisella Tularensis)
Market Concerns
Safety Factor
Development Delays
Storage Problems
Perfluorocarbons as Alternative to Overcome Storage Problems
Costs
Standards for Vaccine Safety and Quality

4. DISTRIBUTION CHANNELS5. TECHNOLOGICAL DEVELOPMENTS

Applying Gene Therapy to Develop Therapeutic Solutions
Research and Trials of AIDS Vaccines
Ongoing Clinical Testing for AIDS Vaccines: Status As of 2010
International AIDS Vaccine Initiative (IAVI)
Cancer
Cancer Type and Area Effected
Immunotherapies for Cancer
Cancer Treatment Drugs
Issues Effecting the Development of Commercially Viable Cancer Vaccines
Frequency of Vaccination
Growth Boosters in the Cancer Vaccines Market
Available Cancer Treatment Vaccines
Select Cancer Vaccines (Therapeutic and Prophylactic) in Clinical Trials: As of 2010
Other Cancer Treatment Vaccines
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines

6. CLINICAL TRIALS IN THE VACCINES MARKET

Vaccinogen Selects Clinipace for Phase 3b Clinical Trial with OncoVAX
BioSante to Restart Prostate Cancer Vaccine Clinical Testing
University of Oxford to Commence Phase 2b Proof-of- Concept Clinical Trials with TB Vaccine in Infants
Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax Treatment

7. RESEARCH BREAKTHROUGHS – A HISTORIC PERSPECTIVE BUILDER

Favrille Announces Phase III Registration Trial Results of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Novartis Announces Phase III Results of Menveo® Vaccine
Emergent Commences Phase II Clinical Study of Typhoid Vaccine
AVANT’s Single-Dose Oral Ty800 Vaccine Meets Key Endpoints
Emergent BioSolutions’ Typhoid Vaccine Completes Final Phase II Clinical Trial
Antigenics Announces Positive Data on Phase-I Study of ACAM-FLU-ATM Vaccine
Bavarian Nordic’s IMVAMUNE® Post-Exposure Vaccination Demonstrates Protection Against Fatal Poxvirus Infection
BSU Scientists to Commence Human West Nile Vaccine Development Project
Intercell Concludes First Phase Clinical Studies of IC31® Adjuvanted Influenza Vaccine
Protherics Commences Phase 2 Angiotensin Vaccine Study
Novartis Receives European Approval for Optaflu® Flu Vaccine
CSL Biotherapies Files BLA for Influenza Vaccine
Orchestra Therapeutics Abandons Development of HIV Vaccine
AlphaVax Concludes Phase I Clinical Trial of Flu Vaccine
AVANT Presents Preclinical Data on Enteric Vaccine
Baxter Declares Results of Seasonal Flu Vaccine Candidate Trial
IDM Pharma Announces Interim Data of Phase II Clinical Trials of Lung Cancer Vaccine
Novavax Announces Developments in Discovery Program
Acambis Pioneers Testing of West Nile Virus Vaccine in Grown Ups
Acambis Initiates Test of single-dose JE vaccine in India
AVAX Technologies Initiates Phase 3 Clinical Trial For M-Vax
LigoCyte Pharmaceuticals Begins Clinical Testing of Norovirus Vaccine
Alphavax Initiates Clinical Testing for Flu and CMV Vaccines
Sanofi Pasteur Begins Phase 2 Testing of New Influenza Vaccine
Antigenics Reveals the Preliminary Data of Clinical Trial of Oncophage®
Baxter Reveals Phase I/II Clinical Trial Results of H5N1 Pandemic Vaccine
Crucell and AERAS Initiates Tuberculosis Vaccine Clinical Trial
DOR BioPharma Announces Phase I Results of RiVax™
GlaxoSmithKline Starts Clinical Trials to Test H5N1 Pandemic Flu Vaccines
MedImmune Initiates Phase I Clinical Trial of Avian H5N1 Vaccine
MedImmune Reveals Results of Phase 3 Study for CAIV-T
MedImmune Initiates Second Phase 1 Study with MEDI-534
Sanofi Pasteur Initiates First Clinical Trial of Cell Based H7N1 Vaccine
Therion Biologics Completes Enrollment for Phase III trials of PANVAC-VF
ViRexx Finishes the Treatment in Phase I Study of Hepa Vaxx B Vaccine
Antigenics Begins Phase I Clinical Trial of AG-707
Positive Results in Novavax’s Pandemic Influenza Vaccine Pre-clinical Trials
Trials Reveal H5N1 Pre-Pandemic Vaccine of Sanofi Pasteur Effective
PowderMed Reveals Results for Phase 1 Trials for Influenza Vaccine
Phase II clinical trials of China's hepatitis B vaccine
Findings Prove New Nose-Spray Vaccines Effective
Large Doses of H5N1 Influenza Vaccine Appears Effective
New Vaccine Technology to Prevent TB
HPV Vaccine to Help Prevent Cervical Cancer
Scientists Develop H7N1 Avian Influenza Vaccine
Human H5N1 Vaccine Developed by Central Hygiene and Epidemiology Institute

8. PRODUCT DEVELOPMENT/LAUNCHES

Vivalis and SAFC Launch Ex-Cell EBx Media

9. PRODUCT DEVELOPMENT/LAUNCHES – A HISTORIC PERSPECTIVE BUILDER

MSD Pharmaceuticals India Launches GARDASIL Vaccine
Sanofi-Aventis Introduces ActHIB Vaccine in Japan
Sinovac Biotech Introduces Anflu®
Nventa Biopharmaceuticals Develops Poly IC-Poly Arginine
Replikins Develops New Synthesized Vaccine
GlaxoSmithKline Biologicals Launches Cervarix
CSL Develops New Vaccine for Prevention of Bird Flu
GlaxoSmithKline to Introduce Five Key Medicines for Oncology
FFF Enterprises Unveils My Flu Vaccine Network
Nabi Biopharmaceuticals to Develop NicVax Vaccine for Reducing Nicotine Effects
GenPhar Develops Highly Effective Tetravalent Dengue Vaccine
Iomai Commences the Development of Prophylactic Traveler™s Diarrhea Vaccine
Biological Immunological to Produce and Sell r-Hepatitis B Vaccine
Thailand Researchers Commence the Development of Human Bird Flu Vaccine
USV to Commercialize Typhoid Vaccine
ALK-Abelló Introduces GRAZAX® Anti-Allergy Vaccine
Novartis Unveils Influenza Virus Vaccine Fluvirin®
Wyeth Introduces Latest 7-in-1 Pneumococcal Conjugate Vaccine
Intervet Releases Arnhem, a Prototype of Avian Influenza Vaccine
Shantha Launches ‘Jencevac’ Brain Fever Vaccine
Wockhardt and Zhejiang Introduces New Hepatitis- A Vaccine
GSK Introduces Rotarix(R) Vaccines for Infants
Sinovac Biotech Introduces Bilive™

10. RECENT INDUSTRY ACTIVITY

‘Sanofi-Aventis’ Name Turns Simpler, Now Known as Just ‘Sanofi’
Antigenics Changes Name to Agenus, Provides Pipeline Details
AltraVax Acquires Vaccine Development Technology Package from Maxygen
Pfizer Integrates R&D operations of Wyeth
Dendreon Receives FDA Approval for PROVENGE® Vaccine to Treat Men with Advanced Prostate Cancer
SVA and Parenteral Biotech Enter into a Partnership to Distribute and Supply Vaccines
Novartis Obtains FDA Approval for Menveo® Vaccine
Pfizer to Supply Vaccine for Pneumococcal Disease
Torii Enters into Partnership with Riken
Sanofi-Aventis Acquires Shantha Biotechnics
Affitech AS Merges with Pharmexa A/S
Takeda Acquires IDM Pharma
Pfizer Concludes Wyeth’s Acquisition
Sanofi Pasteur and Syntiron Sign Agreement to Develop and Market Prophylactic Vaccine
Cell Genesys Merges with BioSante Pharmaceuticals
Simcere Pharmaceutical Acquires Controlling Stake in ChinaVax
Novartis to Acquire 85% Stake in Zhejiang Tianyuan
FDA Approves Merck’s Gardasil for Males under 9 to 26 Years Age
Merck Sign Agreement with CSL Biotherapies
Sinovac Forms JV with Dalian to Develop and Market Human-Use Vaccines
CPL Enters Into JV with Novavax
Nobilon Ties-up with WHO
GeoVax Labs to Relocate Operations
SingVax and Inviragen Merge
Sanofi-aventis and Mexican Authorities Enter into Agreement
Kitasato Institute and Daiichi Sankyo Ink Agreement
ACVD to Enter into Alliance with Emory Vaccine Center
Emory University to Set Up Emory Institute for Drug Discovery
ImmunoVaccine Technologies Enters into Partnership with FIT Biotech
VGX Pharmaceuticals Merges with Inovio Biomedical
Sanofi Pasteur Obtains EC Approval for INTANZA®/IDflu®
European Commission Grants Marketing Authorization to Ixiaro® Vaccine
US FDA Approves Ixiaro® Vaccine
Emergent BioSolutions Purchases Protein Sciences
Vaccine Technologies Signs Agreement with Celldex Therapeutics
Oxford-Emergent Tuberculosis Consortium and ProBio Gen Ink Agreement
JN-International to Acquire Biocor’s Vaccine Research and Manufacturing Plant
Mymetics to Acquire Bestewil Holding BV
Eureka Genomics and Nanobac Pharmaceuticals to Merge
Immunovaccine Enters into Agreement with National Cancer Institute
GSK Forms Joint Venture with Walvax

11. STRATEGIC CORPORATE DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER

AVANT Adopts New Identity as Celldex Therapeutics
Eli Lilly Takes Over ImClone Systems
Sanofi Pasteur Acquires Acambis
Novartis to Acquire Protez
Novartis Inks Agreement with AlphaVax
Vacsera Signs Agreement with Omninvest
GeoVax Sign LOI with Vivalis
GlaxoSmithKline Receives EC Approval for Prepandrix Vaccine
ShigaMedix SAS and Avesthagen Sign Agreement
Shenzhen Neptunus Inks Agreement with Glaxo SmithKline
Sanofi Pasteur Establishes Vaccine Manufacturing Facility
Emergent BioSolutions Forges Joint Venture with the University of Oxford
Crucell Bags Contract from NIAID and NIH
PharmAthene Takes Over Business of Avecia
Crucell and Wyeth Pharmaceuticals Sign Agreement
Cytos Biotechnology and Pfizer Vaccines Sign Agreement
Intercell Acquires Iomai
Emergent BioSolutions to Acquire Recombinant Flu Vaccine, FluBlok®
Encorium Group Signs Contract with Protherics
Beijing Keyuan Xinhai Pharmaceutical Signs Agreement with China Biopharma
Callisto Merges with Celldex
Mymetics Corp. Buys Preventive Malaria Vaccine of Pevion Biotech AG
Dynavax Inks Agreement with Novartis
NasVax to Buy Protea Vaccine Technologies
Paladin Labs Buys ViRexx Medical Corp
Emergent BioSolutions Acquires Group of Anthrax Monoclonal Antibodies from AVANIR
China Biopharma and BKXPC Enter into Agreement
Encorium Signs Contract with Protherics for Phase 2 Trial of ATV for Hypertension
GenPhar to Establish Vaccine Production Plant in South Carolina
Intercell Partners SSI and Sanofi Pasteur to Further Develop TB Vaccine
Intercell and PATH Malaria Vaccine Initiative Form New Partnership for Malaria Vaccine
Intercell Receives Manufacturer's License for Production of JE Vaccine
GSK Receives US FDA Approval for ROTARIX® Rotavirus Vaccine
Dynavax and Merck & Co Announce Clinical Hold of HEPLISAV Vaccine Trial
Pharmexa and Ichor Enter into Co-Development Agreement for Multiple DNA Vaccines
Crucell Enters into Exclusive Development Agreement with Wyeth Pharmaceuticals
Crucell and Sanofi Ink an Agreement for Advanced Anti-Rabies Biologicals
FDA Confers Priority Designation for Supplemental Application for GARDASIL ®
Sanofi Submits a European Marketing Approval Application for First Influenza Vaccine
Lonza Consolidates Micobial Biopharma Operations
Novartis Acquires Rights Over a Novel Therapeutic Vaccine Candidate
AstraZeneca Purchases MedImmune
Nobilon Purchases EBx™ Cell Lines Rights from Vivalis
NasVax Inks Partnership Agreement with SciGen
GSK Inks Co-Promotion Agreement with Sinovac Biotech for Anflu
Pfizer Buys Coley Pharmaceutical Group
FDA Selects sanofi’s H5N1 Vaccine
Novartis Starts Construction of a Cell-Culture Based Vaccine Production Facility
IVT Signs an MoU to Take Over Immunotope
Oxford BioMedica Takes Over Oxxon Therapeutics
DND Issues RFP for acquisition of MVA-based smallpox vaccine
GlaxoSmithKline Acquires Reliant Pharmaceuticals
GSK Acquires Praecis Pharmaceuticals
Berna Biotech Divests Stake in Pevion Biotech
GeoVax Signs a Private Placement Agreement with Pure Capital
Crucell Inks a Research License Agreement with ISU ABXIS of Korea
China Biopharma Concludes Capital Funding to ZT Biotech
Crucell and Acambis Ink a Licensing Agreement for PER. C6 ® Technology
Novartis and Intercell Join Hands to Advance Vaccine Programs
Serum Institute and Akorn Ink MoU for Vaccine Commercialization in US Market
Merck Plans to Establish a Human Vaccine Facility in Ireland
Schering-Plough Acquires Organon Bio Sciences
Intas Biopharmaceuticals Enters into Collaboration Agreement with Virionics
Oxxon Therapeutics Starts U. S. Operation
GenPhar and ImmuneRegen Enter into Research Partnership
Intercell Submits BLA for JE Vaccine to US FDA
AVANT and Select Vaccines Enter into R&D Partnership
AVAX Enters into Agreement with Cancer Treatment Centers of America
CSC’s DVC and Baxter Receive Contract Modification from U. S. HHS
DOR BioPharma Enters into CRADA with Walter Reed Army Institute
Dynavax and Merck to Enter into Partnership to Develop Hepatitis B Vaccine
Emergent BioSolutions Commences Delivery of Bio Thrax® to US Health Department
Maxygen and Sanofi Pasteur sign License Agreement
Beijing Public Health Bureau Enters into Purchase Agreement with Sinovac
Novartis Wins US Government Contract for Developing Antigen Technology
MedImmune Announces Licensing of Reverse Genetics Technology to GlaxoSmithKline
MedImmune Wins US Government Contract
MedImmune and Human Genome Sciences Sign Lease Agreement
Acambis Announces Signing of Collaboration Agreement with Sanofi Pasteur
Acambis Announces JE Partnership Agreement with Sanofi Pasteur
Crucell Procures Major Patent for Influenza Vaccine Production
CSL Receives FDA Approval for Influenza Virus Vaccine
GlaxoSmithKline Inks Contract with UK Government
Merck & Co. , Inc. and Dynavax to Jointly Develop Hepatitis B Vaccine
Sanofi Pasteur Wins Contract to Design, Retrofit and Maintain Influenza Vaccine Unit
Sanofi Pasteur Completes Construction of Influenza Vaccine Production Unit
Amgen Acquires Abgenix
Pfizer Acquires PowderMed
CancerVax and Micromet Merge to Establish Micromet, Inc.
Novartis Acquires Chiron
Dynavax Takes Over Rhein Biotech
AnGes and Vical Ink Collaborative Agreement
GeoVax Merges with Dauphin
Hawaii Biotech and Avantogen Merge to Form New Entity
CytoDyn Acquires Advanced Influenza Technologies
Emergent BioSolutions Acquires VIVACS
Acambis Divests Berna Business to Crucell
Novavax Inks an Agreement with Bharat Biotech to Develop Avian Flu Vaccine
Aeras Receives License for Developing and Distributing Tuberculosis Vaccine
Acambis to Supply Smallpox Vaccine to CDCP
AlphaVax and Wyeth Enhance Existing Licensing Agreement
Baxter Enters into a Contract to Supply Pandemic Influenza Vaccine
Sanofi Pasteur Signs Stockpile Contract with the US Government
Crucell Licenses PER. C6® Technology to ADImmune Corporation
Baxter Wins Stockpile Production Contract for H5N1 from the NHS
Crucell Earns NIH Contract to Develop HIV Vaccine
Novartis Secures Stockpile Supply Contract from the US Government
Novartis Signs Distribution Agreement with Intercell
GSK Receives Stockpile Supply Contract for Fly Pandemic from the HHS
GSK Signs H5N1 Antigen Influenza Vaccine Contract with Switzerland
DOR BioPharma Forms Alliance to Develop Ricin Vaccine
Nobilon and NVI to Jointly Develop RSV Vaccine
SciGen and OctoPlus Join Forces to Develop Hepatitis B Vaccine Delivery
AlphaVax Receives Patent for Alphavaccines Manufacturing Process
IVI Receives Funds for Cholera Vaccine Development Program
Novavax Forms Strategic Alliance with US-based, PacificGMP
Sanofi Pasteur Enters into Partnership with PDVI
MedImmune Inks a Cooperative R&D Agreement with NIAID
MedImmune Bags a Five-Year HHS Contract
Novavax Enters into a Cooperative Research Agreement with CDC
GlaxoSmithKline Establishes New Vaccine Manufacturing Facility
GenPhar Extends R&D Contract with NMRC
Medlmmune Files for INDA with FDA for a New Influenza Vaccine
Rotarix™ Vaccines Receives European Approval
Merck’s GARDASIL® Receives FDA Approval
CDC Adds Merck’s GARDASIL® Under its VFC Category in the US
Medlmmune Submits sBLA to the FDA Refrigerator-Stable Influenza Vaccine
Medlmmune Submits sBLA to the FDA for Expanded Label for CAIV-T
Medlmmune Receives FDA Approval for the Use of Reverse Genetics Technology
Vivalis Starts a New Plant in France to Produce Viral Vaccines
Fiocruz Provides Yellow-Fever Vaccine to Peruvian Government
Merck Receives FDA Approval for Zostavax Vaccine
The US Health and Human Services Department Awards Grant to Pharma Companies
GlaxoSmithKline Expands License and Supply Agreement with Antigenics
GlaxoSmithKline Applies for Approval for Cervical Cancer Vaccine
Omnia Biologics Signs Deal with Aeras Global TB Vaccine Foundation
Aeras Alliances with Dutch Scientific Organizations to Develop Latest TB Vaccines
Embrex, Shenzhen, and P. R. China Team Up for Manufacturing Influenza Vaccine
Health Canada Grants Approval to Merck’s RotaTeq
HepaLife Technologies Receives License for Technology from MSU
Hindustan Latex Ties-up with Bharat Biotech for Marketing Vaccines
Emergent BioSolutions and Sanofi Pasteur Sign Agreement
USV and BCIL Enter into Agreement
GenVec Receives Fifth-Year Extension of Contract from NIAID
Inovio Joins Hands with Tripep to Develop Hepatitis C Vaccine
Novavax and Bharat Biotech Form Alliance to Develop Pandemic Flu Vaccine
Panacea Biotech Joins Hands with NVI to Create Polio Vaccine
Immune Response Ties Up with Accelsiors for Trial of NeuroVax Vaccine
Nordic Vaccine Joins Forces with Ace BioSciences to Develop Efficient Vaccines
Eisai Partners with DNAVEC to Develop New Vaccine
ViRexx Partners with DRDC to Develop Biodefence Vaccines
Biovirx Teams Up with IDT to Reintroduce Vaccine for Infants
LG Life Sciences Enters into Agreement with Sinovac
MediGene Awards Licenses to Virionics for CVLP Vaccine Program
FluLaval Influenza Vaccine Receives FDA Approval
Merck Applies for Approval to Market Gardasil in China
Bio-Bridge Establishes New Vaccine Facility in China
SIIL Established the First-ever Biotech SEZ in India
Aeras Foundation Establishes New Laboratory for TB Vaccine
China Biopharma Distributes Flu Vaccine in China
ViroPro Founds New Subsidiary for Developing Medicinal Vaccines

12. FOCUS ON SELECT GLOBAL PLAYERS

ALK – Abelló A/S (Denmark)
Bavarian Nordic A/S (Denmark)
Crucell N. V. (The Netherlands)
CSL Ltd. (Australia)
GlaxoSmithKline PLC (UK)
GlaxoSmithKline Biologicals S. A (Belgium)
Medimmune, Inc. (USA)
Merck & Company, Inc. (USA)
Novartis Vaccines & Diagnostics, Inc. (USA)
Sanofi (Formerly Sanofi-Aventis SA) (France)
Sanofi Pasteur, SA (France)
Sanofi Pasteur Inc. (USA)
Shantha Biotechnics Ltd. (India)
Vaxin, Inc. (USA)
Wyeth (USA)

13. GLOBAL MARKET PERSPECTIVE

Table 31. World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 32. World Historic Review for Human Vaccines (Prophylactic) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 33. World 15-Year Perspective for Human Vaccines (Prophylactic) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 34. World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Segment – Pediatric and Adult Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 35. World Historic Review for Human Vaccines (Prophylactic) by Product Segment – Pediatric and Adult Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 36. World 15-Year Perspective for Human Vaccines (Prophylactic) by Product Segment – Percentage Breakdown of Dollar Sales for Pediatric and Adult Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 37. World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 38. World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 39. World 15-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 40. World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 41. World Historic Review for Adult Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 42. World 15-Year Perspective for Adult Prophylactic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 43. World Recent Past, Current & Future Analysis for Human Vaccines (Therapeutic) – Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

III. MARKET1. THE UNITED STATES

A. Market Analysis
Outlook
Growth Drivers
Market Constraints
Supply Shortages Mar Vaccines Market in Early Part of the Decade
Pediatric Vaccines Market
Market Focus Shifting From Pediatric Vaccines
Growth Drivers for US Pediatric Vaccines Market
Demand Restraining factors for US Pediatric Vaccines Market

Table 44. US Historic Review for Pediatric Vaccines: Annual Sales (In Millions of Doses) for Years 2000 through 2005 (includes corresponding Graph/Chart)
Table 45. US Pediatric Vaccines by Type in terms of Percent of Doses: 2000-2005 (includes corresponding Graph/Chart)

‘Bright’ Outlook for Therapeutic Vaccines
Select Cancer Vaccines in Pipeline in the US: As of 2010
Market Share of Key Players in North America

Table 46. Leading Players in the North American Human Vaccines Market (2005 – A Recent Past Review): Market Share Breakdown of Value Sales for Merck, Sanofi-Aventis, Wyeth, Glaxo SmithKline and Others (includes corresponding Graph/Chart)

The US Influenza Vaccine Market

Table 47. The US Influenza Vaccine Market: Production and Distribution of Influenza Vaccine (In Millions) for the Period 2000-2001 to 2007- 2008 (includes corresponding Graph/Chart)

US DHHS Allocates US$1 Billion for Developing H1N1 Vaccine in 2009

2007-2008 INFLUENZA VACCINE SEASON

Table 48. Influenza Vaccine Producers for the Influenza Season (2007-2008): Market Share Breakdown in Production Terms for Sanofi Pasteur, Novartis, GlaxoSmithKline, MedImmune, and CSL (includes corresponding Graph/Chart)

2005-2006 INFLUENZA VACCINE SEASON

Table 49. Funds Forwarded by HHS for Influenza Vaccine Production (2005-2006) to Key Vaccine Manufacturers (In US Dollars) (includes corresponding Graph/Chart

Influenza Vaccine Producers for the 2006-2007 Influenza Season
Problems Effecting Timely Supply of Influenza Vaccine

Table 50. Influenza Vaccines Market in the US (2005 – A Historic Review): Percentage Breakdown of Value Sales for Sanofi Aventis, Chiron , GSK, and Medimmune (includes corresponding Graph/Chart)

Key Statistics

Table 51. Number of Children (In Millions) Under 5 Years of Age in the US: 2000-2005 (includes corresponding Graph/Chart)

Vaccines and Intended User Group
Need for Immunization Schedule for Adults
Adult Population: To Drive Future Growth of Pertussis Vaccines Market

Table 52. Pertussis Cases (In Millions) for Years 2000 through 2008 (includes corresponding Graph/Chart)

Federal Research & Grants
National Cancer Institute
National Institutes of Health (NIH)
NIH Scientists Showcase Potential West Nile Virus Vaccine
NIH Doles Out Grants to Biotech Companies
Development Funds for HIV Vaccines- Recent Past Data
Development Funds for Biodefense-Related Vaccines-Recent Past Data
The National Institute of Allergy and Infectious Diseases (NIAID)
Intramural Research
Extramural Divisions
Vaccine Pricing in the US

Table 53. Vaccine Prices (In US$ per Dose) in the US: 2002-2005 (includes corresponding Graph/Chart)

Regulatory Environment
Review Process Make Vaccines Safer
Imports-Exports Scenario: A Historic Perspective
Exports of Human Vaccines for 2004

Table 54. US Domestic Exports of Vaccines for Human Medicine for the Year 2004 (Value in ‘000 US Dollars) (includes corresponding Graph/Chart)

Imports of Human Vaccines for 2004

Table 55. US Imports of Vaccines for Human Medicine for the Year 2004 (Value in ‘000 US Dollars) (includes corresponding Graph/Chart)

Select Players
Alphavax, Inc.
Agenus Inc. (Formerly Antigenics, Inc. ) (USA)
Antigenics, Inc.
Avax Technologies, Inc.
Baxter International, Inc.
Celldex Therapeutics, Inc.
Dendreon Corporation
Dynavax Technologies Corp.
Emergent BioSolutions Inc.
GenPhar, Inc.
Ligocyte Pharmaceuticals, Inc
Maxygen, Inc.
Micromet, Inc.
Novavax, Inc.
Progenics Pharmaceuticals, Inc.
Soligenix, Inc.
B. Market Analytics

Table 56. US Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 57. US Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment –Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 58. US 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis

2009 H1N1 PANDEMIC BOOSTS VACCINES SALES

H1N1 Vaccines Approved For Use in Canada
B. Market Analytics

Table 59. Canadian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 60. Canadian Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 61. Canadian 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3. JAPAN

Market Analysis

Table 62. Japanese Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 63. Japanese Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 64. Japanese 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Overview

Table 65. Leading Players in the West European Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmith Kline, Wyeth, Novartis, and Others (includes corresponding Graph/Chart)

Vaccine Pricing in Europe
Major Drawbacks
Regulatory Mechanism for Vaccines in Europe
Sanofi Pasteur MSD (Europe) – A Leading Player
Market Share Statistics by Vaccines Category

Table 66. Leading Players in the European Pediatric Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Wyeth, Sanofi Pasteur MSD, and Others (includes corresponding Graph/Chart)
Table 67. Leading Players in the European HPV Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, and GlaxoSmithKline (includes corresponding Graph/Chart)
Table 68. Leading Players in the European for Flu, and Other Adult Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Novartis, Solvay, and Others (includes corresponding Graph/Chart)
Table 69. Leading Players in the European Booster Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Glaxo SmithKline, and Others (includes corresponding Graph/Chart)
Table 70. Leading Players in the European Travel Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Sanofi Pasteur MSD, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 71. European Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 72. European Historic Review for Human Vaccines (Prophylactic) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 73. European 15-Year Perspective for Human Vaccines (Prophylactic) by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 74. European Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 75. European Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 76. European 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis

Table 77. Leading Players in the French Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Wyeth, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 78. French Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 79. French Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 80. French 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis

Table 81. Leading Players in the German Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Sanofi Pasteur MSD, Novartis, Wyeth, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 82. German Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 83. German Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 84. German 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4C. ITALY

A. Market Analysis

Table 85. Leading Players in the Vaccines Market in Italy (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, Novartis, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 86. Italian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 87. Italian Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 88. Italian 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis

Table 89. Leading Players in the Vaccines Market in the UK (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart)

The UK Vaccine Industry Group (UVIG)
Select Players
BioVex
Oxford Biomedica PLC
B. Market Analytics

Table 90. UK Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 91. UK Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 92. UK 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4E. SPAIN

A. Market Analysis

Table 93. Leading Players in the Vaccines Market in Spain (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 94. Spanish Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2009 through 2017 (includes corresponding Graph/Chart)
Table 95. Spanish Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 96. Spanish 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4F. RUSSIA

A. Market Analysis

Table 97. Leading Players in the Russian Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, GlaxoSmithKline, Merck & Co. , Novartis, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 98. Russian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 99. Russian Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 100. Russian 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

A. Market Analysis

Table 101. Leading Players in the Vaccines Market in Rest of Europe (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart)

Select Player
Intercell AG (Austria)
B. Market Analytics

Table 102. Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 103. Rest of Europe Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 104. Rest of Europe 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Asian Vaccine Industry
Challenges
China

Table 105. Leading Players in the Vaccines Market in China (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)

Domestic Firms Occupy Major Share, Private/Foreign Companies Increase Market Share
Growth Drivers

Table 106. Central Government Funding for National Immunization Program (2004- 2008) (includes corresponding Graph/Chart)

State Drug Administration: Regulatory Authority in China
Imports of Vaccines
Coverage and Reimbursements
Research in Therapeutic Vaccines
India

Table 107. Leading Players in the Vaccines Market in India (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur (plus Shanta), Glaxo SmithKline, Serum Institute of India, Novartis, Panacea, Others (includes corresponding Graph/Chart)

Development Pipeline
Hepatitis B Vaccine in India
Panacea Biotec: A Leading Manufacturer of Hepatitis B Vaccine
Combination Vaccines
Indian Vaccine Market - Combination Vaccines Available in the Country
Indian Vaccine Market: New Combination Vaccines under Development by Major Companies As of 2010
International Players Entering the Arena
Major Partnerships Between Indian and International Players: A Recent Past Data
Heading Towards Greener Pastures
The Patent Act (Third Amendment), 2005
Select Players
GreenCross Vaccine Co. , Ltd. (South Korea)
Human Biologicals Institute (India)
Panacea Biotec Limited (India)
Serum Institute of India, Ltd. (India)
Wockhardt Limited (India)
B. Market Analytics

Table 108. Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 109. Asia-Pacific Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 110. Asia-Pacific 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

6. LATIN AMERICA

A. Market Analysis
Overview

Table 111. Leading Players in the Vaccines Market in Latin America (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, Wyeth, GlaxoSmith Kline, Merck, Novartis, and Others (includes corresponding Graph/Chart)

Need for an effective TB Vaccine in Brazil
B. Market Analytics

Table 112. Latin American Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 113. Latin American Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 114. Latin American 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

7. REST OF WORLD

Market Analysis

Table 115. Rest of World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 116. Rest of World Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 117. Rest of World 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 162 (including Divisions/Subsidiaries - 194)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Latin America
Africa
Middle-East
Skip to top


Ask Your Question

Human Vaccines: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: